KCNK15 and thyroid gland carcinoma: The results revealed that high expression of KCNK2 (HR=3.34, 95% CI: 1.25-8.92, and p=0.011), KCNK3 (HR=3.14, 95% CI: 1.17-8.44, and p=0.017), KCNK12 (HR=5.02, 95% CI: 1.14-22.08, and p=0.018) was associated with a worse overall survival rate in the thyroid carcinoma patients while high expression of KCNK4 (HR=0.36, 95% CI: 0.13-1.01, and p=0.044), KCNK5(HR=0, 95% CI: 0-Inf, and p=0.01), and KCNK15(HR=0.13, 95% CI: 0.03-0.59, and p=0.0019) was associated with a longer overall survival rate (Figure 3).